vs

Side-by-side financial comparison of Linde plc (LIN) and Sunshine Biopharma Inc. (SBFM). Click either name above to swap in a different company.

Linde plc is the larger business by last-quarter revenue ($8.8M vs $8.6M, roughly 1.0× Sunshine Biopharma Inc.). On growth, Linde plc posted the faster year-over-year revenue change (8.2% vs -10.6%). Linde plc produced more free cash flow last quarter ($898.0K vs $-1.6M). Over the past eight quarters, Sunshine Biopharma Inc.'s revenue compounded faster (6.6% CAGR vs -96.7%).

Linde is a global multinational chemical company and the world's largest industrial gas supplier by market share and revenue. Founded by German scientist and engineer Carl von Linde in 1879 in Wiesbaden, Germany, the company is now headquartered in Woking, United Kingdom, and registered in Ireland as Linde plc. Linde plc was formed in 2018 through the merger of Linde AG and Praxair, which was founded in 1907 in the United States as Linde Air Products Company.

Sunshine Biopharma Inc. is a clinical-stage biopharmaceutical company focused on researching, developing and commercializing innovative therapies for oncology, neurodegenerative disorders and infectious diseases. It targets unmet medical needs across global markets, with a pipeline of targeted therapeutic candidates designed to improve patient treatment outcomes.

LIN vs SBFM — Head-to-Head

Bigger by revenue
LIN
LIN
1.0× larger
LIN
$8.8M
$8.6M
SBFM
Growing faster (revenue YoY)
LIN
LIN
+18.9% gap
LIN
8.2%
-10.6%
SBFM
More free cash flow
LIN
LIN
$2.5M more FCF
LIN
$898.0K
$-1.6M
SBFM
Faster 2-yr revenue CAGR
SBFM
SBFM
Annualised
SBFM
6.6%
-96.7%
LIN

Income Statement — Q1 FY2026 vs Q4 FY2025

Metric
LIN
LIN
SBFM
SBFM
Revenue
$8.8M
$8.6M
Net Profit
$-2.1M
Gross Margin
48.5%
35.3%
Operating Margin
27.8%
-20.9%
Net Margin
-25.0%
Revenue YoY
8.2%
-10.6%
Net Profit YoY
0.8%
EPS (diluted)
$3.98

Green = leading value per metric. Periods may differ when fiscal calendars don't align.

8-Quarter Revenue & Profit Trend

Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.

Revenue
LIN
LIN
SBFM
SBFM
Q1 26
$8.8M
Q4 25
$8.8B
$8.6M
Q3 25
$8.6B
$9.4M
Q2 25
$8.5B
$9.4M
Q1 25
$8.1B
$8.9M
Q4 24
$8.3B
$9.6M
Q3 24
$8.4B
$8.4M
Q2 24
$8.3B
$9.3M
Net Profit
LIN
LIN
SBFM
SBFM
Q1 26
Q4 25
$1.5B
$-2.1M
Q3 25
$1.9B
$-883.8K
Q2 25
$1.8B
$-1.8M
Q1 25
$1.7B
$-1.2M
Q4 24
$1.7B
$-2.2M
Q3 24
$1.6B
$-1.2M
Q2 24
$1.7B
$-494.3K
Gross Margin
LIN
LIN
SBFM
SBFM
Q1 26
48.5%
Q4 25
35.3%
Q3 25
32.6%
Q2 25
36.4%
Q1 25
30.7%
Q4 24
32.2%
Q3 24
34.0%
Q2 24
25.3%
Operating Margin
LIN
LIN
SBFM
SBFM
Q1 26
27.8%
Q4 25
23.0%
-20.9%
Q3 25
27.5%
-11.5%
Q2 25
27.7%
-21.8%
Q1 25
26.9%
-14.6%
Q4 24
27.4%
-21.7%
Q3 24
25.0%
-13.1%
Q2 24
26.4%
-13.6%
Net Margin
LIN
LIN
SBFM
SBFM
Q1 26
Q4 25
17.5%
-25.0%
Q3 25
22.4%
-9.4%
Q2 25
20.8%
-18.8%
Q1 25
20.6%
-13.3%
Q4 24
20.8%
-22.5%
Q3 24
18.5%
-14.2%
Q2 24
20.1%
-5.3%
EPS (diluted)
LIN
LIN
SBFM
SBFM
Q1 26
$3.98
Q4 25
$3.28
Q3 25
$4.09
$-0.54
Q2 25
$3.73
$-0.82
Q1 25
$3.51
$-0.44
Q4 24
$3.61
$49.77
Q3 24
$3.22
$-11.61
Q2 24
$3.44
$-43.48

Balance Sheet & Financial Strength

Snapshot of each company's liquidity, leverage and book value from the latest quarter.

Metric
LIN
LIN
SBFM
SBFM
Cash + ST InvestmentsLiquidity on hand
$4.0M
Total DebtLower is stronger
$24.7M
Stockholders' EquityBook value
$40.1M
$23.0M
Total Assets
$86.3M
$30.1M
Debt / EquityLower = less leverage
0.62×

8-quarter trend — quarters aligned by calendar period.

Cash + ST Investments
LIN
LIN
SBFM
SBFM
Q1 26
$4.0M
Q4 25
$5.1B
Q3 25
$4.5B
Q2 25
$4.8B
Q1 25
$5.3B
Q4 24
$4.8B
Q3 24
$5.2B
Q2 24
$4.6B
Total Debt
LIN
LIN
SBFM
SBFM
Q1 26
$24.7M
Q4 25
$20.7B
Q3 25
$18.6B
Q2 25
$19.7B
Q1 25
$17.6B
Q4 24
$15.3B
Q3 24
$17.5B
Q2 24
$16.9B
Stockholders' Equity
LIN
LIN
SBFM
SBFM
Q1 26
$40.1M
Q4 25
$38.2B
$23.0M
Q3 25
$38.6B
$24.2M
Q2 25
$38.5B
$25.7M
Q1 25
$38.0B
$22.7M
Q4 24
$38.1B
$23.5M
Q3 24
$39.2B
$25.0M
Q2 24
$38.2B
$23.5M
Total Assets
LIN
LIN
SBFM
SBFM
Q1 26
$86.3M
Q4 25
$86.8B
$30.1M
Q3 25
$86.0B
$31.5M
Q2 25
$86.1B
$32.0M
Q1 25
$82.7B
$29.2M
Q4 24
$80.1B
$30.6M
Q3 24
$82.5B
$30.1M
Q2 24
$80.2B
$29.3M
Debt / Equity
LIN
LIN
SBFM
SBFM
Q1 26
0.62×
Q4 25
0.54×
Q3 25
0.48×
Q2 25
0.51×
Q1 25
0.46×
Q4 24
0.40×
Q3 24
0.45×
Q2 24
0.44×

Cash Flow & Capital Efficiency

How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.

Metric
LIN
LIN
SBFM
SBFM
Operating Cash FlowLast quarter
$-1.6M
Free Cash FlowOCF − Capex
$898.0K
$-1.6M
FCF MarginFCF / Revenue
10.2%
-18.9%
Capex IntensityCapex / Revenue
0.0%
Cash ConversionOCF / Net Profit
TTM Free Cash FlowTrailing 4 quarters
$4.2B
$-5.5M

8-quarter trend — quarters aligned by calendar period.

Operating Cash Flow
LIN
LIN
SBFM
SBFM
Q1 26
Q4 25
$3.0B
$-1.6M
Q3 25
$2.9B
$-727.8K
Q2 25
$2.2B
$-1.3M
Q1 25
$2.2B
$-1.7M
Q4 24
$2.8B
$-3.4M
Q3 24
$2.7B
$-1.4M
Q2 24
$1.9B
$-4.6M
Free Cash Flow
LIN
LIN
SBFM
SBFM
Q1 26
$898.0K
Q4 25
$1.6B
$-1.6M
Q3 25
$1.7B
$-735.8K
Q2 25
$954.0M
$-1.4M
Q1 25
$891.0M
$-1.7M
Q4 24
$1.6B
$-3.5M
Q3 24
$1.7B
$-1.9M
Q2 24
$796.0M
$-5.6M
FCF Margin
LIN
LIN
SBFM
SBFM
Q1 26
10.2%
Q4 25
17.9%
-18.9%
Q3 25
19.4%
-7.8%
Q2 25
11.2%
-15.2%
Q1 25
11.0%
-19.3%
Q4 24
18.8%
-36.6%
Q3 24
19.9%
-22.2%
Q2 24
9.6%
-59.7%
Capex Intensity
LIN
LIN
SBFM
SBFM
Q1 26
Q4 25
16.6%
0.0%
Q3 25
14.8%
0.1%
Q2 25
14.8%
1.7%
Q1 25
15.7%
0.1%
Q4 24
15.1%
1.1%
Q3 24
12.8%
6.1%
Q2 24
13.7%
10.5%
Cash Conversion
LIN
LIN
SBFM
SBFM
Q1 26
Q4 25
1.98×
Q3 25
1.53×
Q2 25
1.25×
Q1 25
1.29×
Q4 24
1.63×
Q3 24
1.76×
Q2 24
1.16×

Financial Flow Comparison

Revenue → gross profit → operating profit → net profit for each company.

Related Comparisons